Electrochemiluminescence assays for insulin and glutamic acid decarboxylase autoantibodies improve prediction of type 1 diabetes risk

Diabetes Technology and Therapeutics

Volumn 17, Issue 2, 2015, Pages 119-127

  Miao, Dongmei ^a   Steck, Andrea K ^a   Zhang, Li ^a   Guyer, K Michelle ^a   Jiang, Ling ^a   Armstrong, Taylor ^a   Muller, Sarah M ^b   Krischer, Jeffrey ^b   Rewers, Marian ^a   Yu, Liping ^a  

^a UNIVERSITY OF COLORADO DENVER   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; GLUCOSE; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; HEMOGLOBIN A1C; HLA DQ ANTIGEN; HLA DR3 ANTIGEN; HLA DR4 ANTIGEN; INSULIN ANTIBODY; ISLET AUTOANTIBODY; UNCLASSIFIED DRUG; GLUTAMATE DECARBOXYLASE;

ADOLESCENT; ADULT; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CHEMILUMINESCENCE IMMUNOASSAY; CHEMILUMINESCENCE IMMUNOASSAY KIT; CHILD; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; FOLLOW UP; GENOTYPE; GLUTAMIC ACID DECARBOXYLASE 65 AUTOANTIBODY ELECTROCHEMILUMINESCENCE ASSAY; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN AUTOANTIBODY ELECTROCHEMILUMINESCENCE ASSAY; INSULIN DEPENDENT DIABETES MELLITUS; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PATIENT RISK; PREDICTIVE VALUE; PRIORITY JOURNAL; RADIOASSAY; RADIOIMMUNOASSAY KIT; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; DIABETES MELLITUS, TYPE 1; FEMALE; IMMUNOLOGY; LUMINESCENCE; MALE; MASS SCREENING; METABOLISM; PREDIABETIC STATE; VALIDATION STUDY;

AUTOANTIBODIES; DIABETES MELLITUS, TYPE 1; FEMALE; GENOTYPE; GLUTAMATE DECARBOXYLASE; HUMANS; INSULIN ANTIBODIES; LUMINESCENCE; MALE; MASS SCREENING; PREDIABETIC STATE; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY;

EID: 84922463345     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2014.0186     Document Type: Article

References (19)

1. Ziegler AG, Rewers M, Simell O, et al.: Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 2013;309:2473-2479.
2. Achenbach P, Koczwara K, Knopff A, et al.: Mature highaffinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes. J Clin Invest 2004;114:589-597.
3. Mayr A, Schlosser M, Grober N, et al.: GAD autoantibody affinity and epitope specificity identify distinct immunization profiles in children at risk for type 1 diabetes. Diabetes 2007;56:1527-1533.
4. Curnock RM, Reed CR, Rokni S, Broadhurst JW, et al.: Insulin autoantibody affinity measurement using a single concentration of unlabeled insulin competitor discriminates risk in relatives of patients with type 1 diabetes. Clin Exp Immunol 2012;167:67-72.
5. Siljander H, Härkönen T, Hermann R, et al.: Role of insulin autoantibody affinity as a predictive marker for type 1 diabetes in young children with HLA-conferred disease susceptibility. Diabetes Metab Res Rev 2009;25:615-622.
6. Orban T, Sosenko JM, Cuthbertson D, et al.: Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2009;32:2269-2274.
7. Achenbach P, Warncke K, Reiter J, et al.: Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics. Diabetes 2004;53:384-392.
8. Bonifacio E, Scirpoli M, Kredel K, et al.: Early autoantibody responses in prediabetes are IgG1 dominated and suggest antigen-specific regulation. J Immunol 1999;163:525-532.
9. Couper JJ, Harrison LC, Aldis JJE, et al.: IgG subclass antibodies to glutamic acid decarboxylase and risk for progression to clinical insulin-dependent diabetes. Hum Immunol 1998;59:493-499.
10. Williams AJK, Lampasona V, Schlosser M, et al.: Nterminally truncated GAD discriminates progression in GAD antibody positive relatives of patients with type 1 diabetes [abstract]. Diabetologia 2013;56(Suppl 1):S25.
11. Yu L, Miao D, Scrimgeour L, et al.: Distinguishing persistent insulin autoantibodies with differential risk: nonradioactive bivalent proinsulin/insulin autoantibody assay. Diabetes 2012;61:179-186.
12. Yu L, Dong F, Fuse M, et al.: Proinsulin/insulin autoantibodies measured with electrochemiluminescent assay are the earliest indicator of prediabetic islet autoimmunity. Diabetes Care 2013;36:2266-2270.
13. Miao D, Guyer KM, Jiang L, et al.: GAD65 autoantibodies detected by electrochemiluminescence (ECL) assay identify high risk for type 1 diabetes. Diabetes 2013;62:4174-4178.
14. Yu L, Boulware DC, Beam CA, et al.: Zinc transporter-8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodies. Diabetes Care 2012;35:1213-1218.
15. Mychaleckyj JC, Noble JA, Moonsamy PV, et al.: HLA genotyping in the international Type 1 Diabetes Genetics Consortium. Clin Trials 2010;7(Suppl):S75-S87.
16. Eisenbarth GS, Gianani R, Yu L, et al.: Dual parameter model for prediction of type 1 diabetes mellitus. Proc Assoc Am Physicians 1998;110:126-135.
17. Wang J, Miao D, Babu S, et al.: Prevalance of autoantibodynegative diabetes is not rare at all ages and increaseswith older age and obesity. J Clin Endocrinol Metab 2007;92:88-92.
18. Steck AK, Johnson K, Barriga KJ, et al.: Age of islet autoantibody appearance and mean levels of insulin, but not GAD or IA-2 autoantibodies, predict age of diagnosis of type 1 diabetes: Diabetes Autoimmunity Study in the Young. Diabetes Care 2011;34:1397-1399.
19. TEDDY Study Group: The Environmental Determinants of Diabetes in the Young (TEDDY) study: study design. Pediatr Diabetes 2007;8:286-298.